Hsbc Holdings PLC Invests $1.13 Million in iRadimed Corporation $IRMD

Key Points

• HSBC Holdings initiated a $1.13 million position in iRadimed during the second quarter, buying 11,993 shares. Institutional investors collectively own 92.34% of the company.
• iRadimed reported quarterly EPS of $0.46, exceeding the $0.44 consensus estimate, while revenue reached $20.47 million. The company also maintained FY 2026 EPS guidance of $2.09–$2.24.
• Shares recently traded at $86.38, down 0.8%, while the company paid a quarterly dividend of $0.20. Analysts maintain a “Moderate Buy” consensus with an average price target of $120, despite two recent rating downgrades to “Hold.”

Hsbc Holdings PLC bought a new position in shares of iRadimed Corporation (NASDAQ:IRMD - Free Report) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 11,993 shares of the medical equipment provider's stock, valued at approximately $1,130,000. Hsbc Holdings PLC owned approximately 0.09% of iRadimed at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its stake in iRadimed by 14.7% in the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider's stock worth $1,354,000 after purchasing an additional 3,307 shares during the period. AQR Capital Management LLC grew its holdings in iRadimed by 7.5% during the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider's stock valued at $831,000 after buying an additional 1,108 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of iRadimed by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider's stock valued at $252,000 after buying an additional 234 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of iRadimed by 8,568.5% during the first quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider's stock valued at $591,000 after buying an additional 11,139 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its position in shares of iRadimed by 1.1% during the first quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider's stock valued at $8,889,000 after buying an additional 1,821 shares during the last quarter. Institutional investors own 92.34% of the company's stock.

iRadimed Trading Down 0.8%

Shares of iRadimed stock opened at $86.38 on Tuesday. The stock has a 50 day moving average of $92.85 and a 200 day moving average of $94.03. iRadimed Corporation has a 12 month low of $67.84 and a 12 month high of $107.90. The firm has a market cap of $1.10 billion, a PE ratio of 48.26 and a beta of 0.90.

iRadimed (NASDAQ:IRMD - Get Free Report) last issued its quarterly earnings data on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.02. iRadimed had a return on equity of 23.45% and a net margin of 26.70%.The business had revenue of $20.47 million for the quarter, compared to analysts' expectations of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, equities research analysts forecast that iRadimed Corporation will post 1.98 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, August 28th. Stockholders of record on Friday, August 14th were issued a $0.20 dividend. The ex-dividend date was Friday, August 14th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed's payout ratio is 44.69%.

Analyst Ratings Changes

IRMD has been the subject of a number of research reports. Wall Street Zen lowered shares of iRadimed from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Weiss Ratings downgraded shares of iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, August 3rd. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, iRadimed currently has a consensus rating of "Moderate Buy" and an average target price of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

Want to see what other hedge funds are holding IRMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iRadimed Corporation (NASDAQ:IRMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source